Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2012

View Archived Issues

Merz Pharma designs novel modulators of mGlu5 receptors

New gamma-secretase modulator shows promise as a cognition-enhancing drug

New method allows drug safety predictions early in drug discovery process

Korean researchers present new siRNA compositions

Gene Signal International discloses novel agents for cancer

Novel drug candidates for Alzheimer's disease presented

Leo Pharma designs new ingenol derivatives

Memorial Sloan-Kettering center launches stem cell trial for beta-thalassemia

Qu Biologics planning phase I/II study in Crohn's disease

FDA approves product for long-term maintenance treatment of COPD

Antisense Therapeutics provides update on ATL-1101

Celgene to request reexamination of CHMP opinion on Istodax MAA

Oxford BioMedica receives funding for ongoing UshStat study

French team synthesizes novel potassium channel blockers

CHMP issues opinion on Dacogen

BrainStorm Cell Therapeutics reports encouraging interim data on NurOwn

NeuroPhage Alzheimer's disease candidate drug set to enter clinic

Collaborating organizations in Belgium and France patent new agents for AIDS

Repros provides update on phase II uterine fibroid trial

Faes Farma out-licenses antiallergy product in Japan

Synergy Pharmaceuticals enters definitive merger agreement

Gene variants may predict fibrosis risk after liver transplant for hepatitis C

BG Medicine files for FDA clearance of ARCHITECT Galectin-3 assay

Berg Pharma kicks off phase I trial of BPM-31543

Enrollment complete in pivotal CompleoTRT trial

Treatment begins in phase II trial of Cerulean's lead product

Phase I trial of XenoPort candidate for RRMS and psoriasis commences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.